Introduction to bisphosphonates. History and functional mechanisms;Einführung in die bisphosphonate. Geschichte und wirkungsmechanismen

Orthopade

Volumn 36, Issue 2, 2007, Pages 103-109

  Fleisch, H ^a  

^a NONE   (Switzerland)

Author keywords

Bisphosphonates; Bone destruction; Mevalonate metabolism; Mineralization; Pyrophosphate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; MEVALONIC ACID; PAMIDRONIC ACID; PYROPHOSPHATE; RISEDRONIC ACID;

ALBERS SCHOENBERG DISEASE; BONE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; IN VIVO STUDY; KIDNEY INJURY; MINERALIZATION; NONHUMAN; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PAGET BONE DISEASE; REVIEW; TREATMENT INDICATION;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM CARBONATE; CALCIUM PHOSPHATES; DIPHOSPHATES; DIPHOSPHONATES; HUMANS; MEVALONIC ACID; OSTEOCLASTS; RATS;

EID: 33847374566     PISSN: 00854530     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00132-006-1040-9     Document Type: Review

References (50)

1. Menschutkin N (1865) Ueber die Einwirkung des Chloracetyls auf phosphorige Säure. Ann Chem Pharm 133: 317-320
2. Fleisch H, Russell RGG, Bisaz S et al. (1968) The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif Tissue Res 2(Suppl): 10-10A
3. Fleisch H, Neuman WF (1961) Mechanism of calcification: role of collagen, polyphosphates and phosphatase. Am J Physiol 200: 1296-1300
4. Fleisch H, Bisaz S (1962) Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 203: 671-675
5. Fleisch H, Bisaz S (1962) Mechanism of calcification: inhibitory role of pyrophosphate. Nature 195: 911
6. 3 in rats. Clin Sci 35: 363-372
7. Fleisch H, Russell RGG, Straumann F (1966) Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212: 901-903
8. Jung A, Bisaz S, Fleisch H (1973) The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 11: 269-280
9. Russell RGG (1965) Excretion of inorganic pyrophosphate in hypophosphatasia. Lancet II: 462-464
10. Russell RGG, Bisaz S, Donath A et al. (1971) Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta and other disorders of bone. J Clin Invest 50: 961-969
11. Francis MD, Russell RGG, Fleisch H (1969) Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165: 1264-1266
12. Francis MD (1969) The inhibition of calcium hydroxyapatite crystal growth by polyphosphonates and polyphosphates. Calcif Tissue Res 3: 151-162
13. Fleisch H, Russell RGG, Bisaz S et al. (1970) The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1: 12-18
14. Fleisch H, Russell RGG, Francis MD (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165: 1262-1264
15. Russell RGG, Mühlbauer RC, Bisaz S et al. (1970) The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res 6: 183-196
16. 2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 11: 196-214
17. Trechsel U, Stutzer A, Fleisch H (1987) Hypercalcemia induced with an arotinoid in thyroparathyroidectomized rats. A new model to study bone resorption in vivo. J Clin Invest 80: 1679-1686
18. Mühlbauer RC, Bauss F, Schenk R et al. (1991) BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6: 1003-1011
19. Mühlbauer RC, Russell RGG, Williams DA, Fleisch H (1971) The effects of diphosphonates, polyphosphates, and calcitonin on "immobilisation" osteoporosis in rats. Eur J Clin Invest 1: 336-44
20. Jee WSS, Black HE, Gotcher JE (1981) Effect of dichloromethane diphosphonate on cortisol-induced bone loss in young adult rabbits. Clin Orthop 156: 39-51
21. Schenk R, Eggli P, Fleisch H, Rosini S (1986) Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38: 342-349
22. Gasser AB, Morgan DB, Fleisch HA, Richelle LJ (1972) The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci 43: 31-45
23. Jung A, Bornand J, Mermillod B et al. (1984) Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat. Cancer Res 44: 3007-3011
24. Martodam RR, Thornton KS, Sica DA et al. (1983) The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor. Calcif Tissue Int 35: 512-519
25. Clézardin P (2002) The antitumor potential of bisphosphonates. Semin Oncol 29(Suppl 21): 33-42
26. Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97(Suppl): 840-847
27. Fleisch H (2000) Bisphosphonates in bone disease. From the Laboratory to the Patient, 4th edn. Academic Press, San Diego San Francisco
28. Hughes DE, Wright KR, Uy HL et al. (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478-1487
29. Sato M, Grasser W, Endo N et al. (1991) Bisphosponate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095-2105
30. Guise TA, Mundy GR (1998) Cancer and bone. Endocr Rev 19: 18-54
31. Van der Pluijm G, Vloedgraven H, van Beek E et al. (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98: 698-705
32. Boissier S, Magnetto S, Frappart L et al. (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57: 3890-3894
33. Shipman CM, Rogers MJ, Apperley JF et al. (1997) Bisphosphonates induce apoptosis in human myeloma cells; a novel anti-tumour activity. Br J Haematol 98: 665-672
34. Luckman SP, Coxon FP, Ebetino FH et al. (1998) Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13: 1668-1678
35. Luckman SP, Hughes D, Coxon FP et al. (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581-589
36. Van Beek, E, Pieterman E, Cohen L et al. (1999) Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264: 108-111
37. Bergstrom JD, Bostedor RG, Masarachia PJ et al. (2000) Alendronate is a specific nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373: 231-241
38. Van Beek E, Lowik C, Van der Pluijm G, Papapoulos S (1999) The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14: 722-729
39. Fisher JE, Rogers MJ, Halasy JM et al. (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 96: 133-138
40. Frith JC, Mönkkönen J, Blackburn GM et al. (1997) Clodronate and liposome-encapsulated clodronate are metabolised to a toxic ATP analog, adenosine5′(b,g-dichloromethylene)triphosphate , by mammalian cells in vitro. J Bone Miner Res 12: 1358-1367
41. Fleisch H, Reszka A, Rodan GA, Rogers M (2002) Bisphosphonates, vol 2: Mechanism of action. In: Bilezikian JP, Raisz LG, Rodan G (eds) Principles of bone biology. Academic Press, San Diego, pp 1361-1385
42. Adami S, Bhalla AK, Dorizzi R et al. (1987) The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41: 326-331
43. Geho WB, Whiteside JA (1973) Experience with disodium etidronate in diseases of ectopic calcification. In: Frame B, Parfitt AM, Duncan H (eds) Clinical aspects of metabolic bone disease. Excerpta Medica, Amsterdam, pp 506-511
44. Smith R, Russell RGG, Bishop M (1971) Diphosphonates and Paget's disease of bone. Lancet I: 945-947
45. Douglas DL, Duckworth T, Russell RGG et al. (1980) Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet I: 1043-1047
46. Siris ES, Sherman WH, Baquiran DC et al. (1980) Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Engl J Med 302: 310-315
47. Reid IR, King AR, Alexander CJ, Ibbertson HK (1988) Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1- bisphosphonate (APD). Lancet I: 143-146
48. Watts NB, Harris ST, Genant HK et al. (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323: 73-79
49. Black DM, Cummings SR, Karpf DB et al. (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535-1541
50. Glorieux FH, Bishop NJ, Plotkin H et al. (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339: 947-952